Veristat’s Post

Advancing therapies intended to treat pediatric patient populations is highly complex with numerous confounding challenges. With this, trial design and conduct come with heightened scrutiny for regulatory, ethical, and safety standards for children as patients. 📽️ Watch our video to learn how we can help you design and run your next pediatric clinical development studies 👇 https://hubs.li/Q02DNj3h0 #Pediatric #RareDiseases

#GCT_NEWS GCT completes enrollment for a Respiratory Pediatric Phase IV Clinical Trial GCT is thrilled to announce the successful completion of enrollment for a Respiratory Pediatric Phase IV Clinical Trial. Notably, we concluded the recruitment phase two months ahead of schedule, a testament to the dedication of our colleagues in Bulgaria and Romania, as well as our motivated Investigators and site staff. This study aims to assess the efficacy and safety of an alcohol-free spray and lozenges in pediatric patients (6-12 years) with sore throat. We are proud to collaborate on this endeavor with our longstanding partner, ZAK-Pharma Dienstleistung Ges.m.b.H. https://lnkd.in/dca7ddj7 #enrollment #patients #pediatric #respiratory #clinicaltrial #CRO #GCT #clinicalresearch #globalclinicaltrials #gctrials #contractresearchorganization #pharma #clinicaloperations #drugdevelopment #GlobalClinicalTrials #clinicaltrials #GCP #biotech #clinicalresearchorganization #collaboration #partnership #sorethroat

This study evaluated the effectiveness of the Standardized Therapy after ECMO Program (STEP), a structured discharge pathway for pediatric ECMO survivors. #DischargePathway #NeurodevelopmentalFollowup #PediatricECMO #PostECMOCare

This study evaluated the effectiveness of the Standardized Therapy after ECMO Program (STEP), a structured discharge pathway for pediatric ECMO survivors. #DischargePathway #NeurodevelopmentalFollowup #PediatricECMO #PostECMOCare

Congress is in discussion of reauthorizing the FDA's Pediatric Rare Disease Priority Review Voucher (PRV) Program. This program has been crucial in accelerating the development and approval of treatments for rare pediatric conditions, enabling life-saving therapies to reach children in need more swiftly. The PRV program incentivizes pharmaceutical companies to prioritize rare diseases, a critical area of healthcare. With its expiration imminent, prompt congressional action is necessary to sustain this vital program. Reauthorizing the PRV program is essential for maintaining progress in the fight against rare pediatric diseases and improving patient outcomes. #HealthcareInnovation #PediatricCare #RareDiseases #FDA

The FDA has announced the release of a draft guidance for industry titled “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment.” Developed by the Division of Gastroenterology within the Center for Drug Evaluation and Research, this guidance aims to assist sponsors in the clinical development of treatments for pediatric ulcerative colitis and Crohn’s disease. It outlines key considerations for study population, design, efficacy, and safety assessments necessary for developing effective treatments for these conditions in children. This initiative underscores FDA’s commitment to improving therapeutic options and outcomes for pediatric patients with inflammatory bowel disease. Know more - https://lnkd.in/e45GyWEj #Pharmacovigilance #ClinicalResearch #FDA #Pediatrics #InflammatoryBowelDisease #DrugDevelopment

Navigating the Challenges of Pediatric Hydrocephalus Treatment in Nepal

Paediatric Rheumatology to improve patient care and outcomes. Stay informed on emerging treatments and research findings in this field. 🧒💊 #PediatricRheumatology #MedicalResearch #HealthcareTech

The clinical application of paediatric serum troponin T testing remains a topic of debate. While serum troponin testing can aid in diagnosing suspected cardiac ischaemia in adults, its utility in paediatric patients with chest pain is limited due to the rarity of cardiac ischaemia in this population. Despite its widespread use in adult populations, current literature suggests caution in relying on serum troponin testing alone for diagnosing chest pain in children, given its multifactorial nature. Further research is needed to determine the optimal diagnostic approach for paediatric patients presenting with chest pain. #Pediatrics #CardiacIschaemia #TroponinTesting 🩺👶❤️

Dr. Faleye Ayodele's manuscript on the context of pediatric rheumatology in Nigeria offers valuable insights into the challenges and progress of the subspecialty. This is one of the PAFLAR's collection on "Promoting Patient-Centered Care for Pediatric Rheumatology Across Africa" published by Frontiers in Paediatrics. Click on the link to read more: https://lnkd.in/dDvVnXdN #PediatricRheumatology #Nigeria #HealthcareResearch"